MetS is a significant public health concern due to its association with severe health outcomes. Early identification and comprehensive management of MetS components are crucial in reducing the global burden of this syndrome. Further research is needed to refine diagnostic criteria, understand the underlying mechanisms, and develop more effective prevention and treatment strategies. The metabolic syndrome (MetS) is a group of illnesses that together better predict a person's risk of cardiovascular disease than any one of the illnesses alone. Human MetS risk is influenced by a combination of environmental and genetic variables. As MetS is a complex disorder with a startlingly high incidence rate these days, developing suitable experimental animal models that closely resemble the illness state in people is essential to resolving the challenges associated with assessing the pathophysiology of MetS in humans. The objective of this study is to provide an overview of the pathophysiology of dietary, genetic, and pharmaceutical models of metabolic syndrome. We will also go over the applicability, advantages, and disadvantages of various animal models. Despite the establishment of many animal models of MetS, more research on.

Antipsychotic drugs, Carbohydrate, Fructose

Alberti G, Zimmet P, Shaw J. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels: International Diabetes Federation; 2006.

Bee Jr YT, Haresh KK, Rajibans S. Prevalence of Metabolic Syndrome among Malaysians using the International Diabetes Federation, National Cholesterol Education Program and Modified World Health Organization Definitions. Malays J Nutr. 2008;14:65–77.

Rampal S, Mahadeva S, Guallar E, Bulgiba A, Mohamed R, Rahmat R, et al. Ethnic differences in the prevalence of metabolic syndrome: results from a multi-ethnic population-based survey in Malaysia. PLoS One. 2012;7:e46365.

Ranasinghe P, Cooray DN, Jayawardena R, Katulanda P. The influence of family history of hypertension on disease prevalence and associated metabolic risk factors among Sri Lankan adults. BMC Public Health. 2015;15:576.

Bonomini F, Rodella LF, Rezzani R. Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis. 2015;6:109–20.

Veronica G, Esther RR. Aging, metabolic syndrome and the heart. Aging Dis. 2012;3:269–79.

Ghezzi AC, Cambri LT, Botezelli JD, Ribeiro C, Dalia RA, de Mello MA. Metabolic syndrome markers in wistar rats of different ages. Diabetol Metab Syndr. 2012;4:16.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.

Aschner P. Metabolic syndrome as a risk factor for diabetes. Expert Rev Cardiovasc Ther. 2010;8:407–12.

Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320–30.

Haggstrom C, Stocks T, Rapp K, Bjorge T, Lindkvist B, Concin H, et al. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer. 2011;128:1890–8.

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35:2402–11.

Bjorge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev. 2010;19:1737–45.

Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol. 2011;2011:351982.

Senaphan K, Kukongviriyapan U, Sangartit W, Pakdeechote P, Pannangpetch P, Prachaney P, et al. Ferulic acid alleviates changes in a rat model of metabolic syndrome induced by high-carbohydrate, high-fat diet. Nutrients. 2015;7:6446–64.

Suman RK, Ray Mohanty I, Borde MK, Maheshwari U, Deshmukh YA. Development of an experimental model of diabetes co-existing with metabolic syndrome in rats. Adv Pharmacol Sci. 2016;2016:11.

Bessesen DH. The role of carbohydrates in insulin resistance. J Nutr. 2001; 131:2782s–6s.

McClenaghan NH. Determining the relationship between dietary carbohydrate intake and insulin resistance. Nutr Res Rev. 2005;18:222–40.

Gadgil MD, Appel LJ, Yeung E, Anderson CA, Sacks FM, Miller 3rd ER. The effects of carbohydrate, unsaturated fat, and protein intake on measures of insulin sensitivity: results from the OmniHeart trial. Diabetes Care. 2013;36:1132–7.

Poudyal H, Panchal S, Brown L. Comparison of purple carrot juice and beta-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome. Br J Nutr. 2010;104:1322–32.

Panchal SK, Poudyal H, Iyer A, Nazer R, Alam A, Diwan V, et al. High-carbohydrate high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol. 2011;57:51–64.

De Natale C, Annuzzi G, Bozzetto L, Mazzarella R, Costabile G, Ciano O, et al. Effects of a plant-based high-carbohydrate/high-fiber diet versus highmonounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care. 2009;32:2168–73.

Bray GA. How bad is fructose? Am J Clin Nutr. 2007;86:895–6. 34. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31 Suppl 1:S61–78.

Jurgens H, Haass W, Castaneda TR, Schurmann A, Koebnick C, Dombrowski F, et al. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res. 2005;13:1146–56.

Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr. 2002;76:911–22.

Rizkalla SW. Health implications of fructose consumption: A review of recent data. Nutr Metab (Lond). 2010;7:82.

Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, et al. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 2004;292:927–34.

Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats. J Comp Physiol B. 2004;174:587–92.

Sanchez-Lozada LG, Tapia E, Jimenez A, Bautista P, Cristobal M, Nepomuceno T, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol. 2007;292:F423–9.

Aguilera AA, Diaz GH, Barcelata ML, Guerrero OA, Ros RM. Effects of fish oil on hypertension, plasma lipids, and tumor necrosis factor-alpha in rats with sucrose-induced metabolic syndrome. J Nutr Biochem. 2004;15:350–7.

Davidoff AJ, Mason MM, Davidson MB, Carmody MW, Hintz KK, Wold LE, et al. Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab. 2004;286:E718–24.

Hintz KK, Aberle NS, Ren J. Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes. Int J Obes Relat Metab Disord. 2003;27:1196–203.

Pang X, Zhao J, Zhang W, Zhuang X, Wang J, Xu R, et al. Antihypertensive effect of total flavones extracted from seed residues of Hippophae rhamnoides L. in sucrose-fed rats. J Ethnopharmacol. 2008;117:325–31.

Oron-Herman M, Kamari Y, Grossman E, Yeger G, Peleg E, Shabtay Z, et al. Metabolic syndrome: comparison of the two commonly used animal models. Am J Hypertens. 2008;21:1018–22.

Brown MA, Storlien LH, Huang X-F, Tapsell LC, Else PL, Higgins JA, et al. Dietary fat and carbohydrate composition: Metabolic disease. 2010.

Buettner R, Scholmerich J, Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring). 2007;15:798–808.

Halade GV, Rahman MM, Williams PJ, Fernandes G. High fat diet-induced animal model of age-associated obesity and osteoporosis. J Nutr Biochem. 2010;21:1162–9.

Xu F, Du Y, Hang S, Chen A, Guo F, Xu T. Adipocytes regulate the bone marrow microenvironment in a mouse model of obesity. Mol Med Rep. 2013;8:823–8.

Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007;86:285–300.

Ghibaudi L, Cook J, Farley C, van Heek M, Hwa JJ. Fat intake affects adiposity, comorbidity factors, and energy metabolism of sprague-dawley rats. Obes Res. 2002;10:956–63.

Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarimde-Lacerda CA. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr. 2010;46:212–23.

Graham LS, Tintut Y, Parhami F, Kitchen CM, Ivanov Y, Tetradis S, et al. Bone density and hyperlipidemia: the T-lymphocyte connection. J Bone Miner Res. 2010;25:2460–9.

Li Y, Lu Z, Zhang X, Yu H, Kirkwood KL, Lopes-Virella MF, et al. Metabolic syndrome exacerbates inflammation and bone loss in periodontitis. J Dent Res. 2015;94:362–70.

Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W, et al. Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res. 2008;77:371–9.

Ae Park S, Choi MS, Cho SY, Seo JS, Jung UJ, Kim MJ, et al. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. Life Sci. 2006;79:1207–13.